ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.
ABRAXANE therapy should not be administered to patients with metastatic breast cancer who have baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE.
Note: An albumin form of paclitaxel may substantially affect a drug's functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS.
ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is an albumin-bound form of paclitaxel with a mean particle size of approximately 130 nanometers. ABRAXANE is supplied as a white to yellow, sterile, lyophilized powder for reconstitution with 20 mL of 0.9% Sodium Chloride Injection, USP prior to intravenous infusion. Each single-use vial contains 100 mg of paclitaxel and approximately 900 mg of human albumin. Each milliliter (mL) of reconstituted suspension contains 5 mg paclitaxel. ABRAXANE is free of solvents. The active agent in ABRAXANE® is paclitaxel, a natural product with antitumor activity. Paclitaxel is obtained from Taxus media.
ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Media Articles Related to Abraxane (Paclitaxel)
Abraxane Approved for Late-Stage Pancreatic Cancer
Source: MedicineNet Pancreatic Cancer Specialty [2013.09.09]
Title: Abraxane Approved for Late-Stage Pancreatic Cancer
Category: Health News
Created: 9/6/2013 4:36:00 PM
Last Editorial Review: 9/9/2013 12:00:00 AM
Published Studies Related to Abraxane (Paclitaxel)
Omega-3 fatty acids are protective against paclitaxel-induced peripheral
neuropathy: a randomized double-blind placebo controlled trial. 
proinflammatory cytokines involved in peripheral neuropathy... CONCLUSIONS: Omega-3 fatty acids may be an efficient neuroprotective agent for
BEAM: a randomized phase II study evaluating the activity of bevacizumab in
combination with carboplatin plus paclitaxel in patients with previously
untreated advanced melanoma. 
metastatic melanoma... CONCLUSION: The study did not meet the primary objective of statistically
[A multicenter, randomized, double-blind, placebo-controlled safety study to
evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC)
alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)]. [Article in Chinese] 
non-small cell lung cancer (NSCLC)... CONCLUSIONS: Compared with TC alone treatmrnt, TC combined with endostar
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with
or without the vascular disrupting agent vadimezan (ASA404) in advanced
non-small-cell lung cancer. 
cancer (NSCLC) versus chemotherapy alone... CONCLUSION: The addition of ASA404 to carboplatin and paclitaxel, although
Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis
from the TAXUS Clinical Trial Program. 
safety and efficacy profile of PES... CONCLUSIONS: In this pooled patient-level analysis from the prospective,
Clinical Trials Related to Abraxane (Paclitaxel)
Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer [Active, not recruiting]
In this study, Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) is being compared to
Taxol® to examine whether the paclitaxel in these 2 formulations undergoes similar processing
by the body. Safety and tolerability of LEP-ETU and Taxol will also be assessed. In this
study, each patient will receive one intravenous infusion of LEP-ETU or Taxol, followed 3
weeks later by an infusion of the other drug, at the same dose and infusion duration.
Multiple blood samples will be taken for analysis before, during, and after both drug
infusions. Upon completing these 2 Cycles of treatment, eligible patients may enroll in an
extension study (LEP-ETU-102B) to continue treatment with LEP-ETU.
LEP-ETU is a liposomal formulation of paclitaxel, a widely used anti-cancer drug. This
LEP-ETU formulation of paclitaxel is being developed to potentially reduce toxicities
associated with Taxol, by eliminating the drug formulation component polyoxyethylated castor
oil (CremophorÂ® EL). In LEP-ETU, paclitaxel is associated with liposomes, which are
microscopic membrane-like structures created from lipids (fats). Thus, the LEP-ETU
formulation could potentially have reduced toxicity, while maintaining or enhancing
Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer [Active, not recruiting]
The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe
as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also
determine if using Abraxane will allow patients to receive treatment every two weeks without
requiring injects of G-CSF, a white blood cell stimulating growth factor.
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis [Active, not recruiting]
The purpose of this study is to investigate the use of systemic intracoronary administration
of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis
following de novo stenting or following angioplasty for in-stent restenosis.
Study of Dose-Dense Adriamycin Plus Cytoxan (AC) Followed by Either Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer [Active, not recruiting]
The primary objective of this study is to compare the safety of dose-dense Abraxane 260
mg/m^2 or Taxol 175 mg/m^2 given every 2 weeks following dose-dense AC chemotherapy.
Bevacizumab will be administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then
at 15 mg/kg every 3 weeks following chemotherapy.
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer [Active, not recruiting]
The purpose of this study is to learn how breast cancer tumors respond to a drug called
Abraxane followed by a combination of 3 chemotherapy drugs commonly used for breast cancer.
Reports of Suspected Abraxane (Paclitaxel) Side Effects
Febrile Neutropenia (24),
Decreased Appetite (21),
White Blood Cell Count Decreased (21), more >>
Page last updated: 2013-09-09